SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?


To: MIKE DOOLEY who wrote (1405)2/9/1998 9:34:00 AM
From: Cisco  Read Replies (1) | Respond to of 1894
 
Mike,

I have been following the NASDAQ question since early December, 1997. Len Prange told me on Dec. 31, 1997 that a formal meeting had been set up with NASDAQ for early in the year and that they fully expected to satisfy NASDAQ and retain their National Listing! I understand that Peter Gombrich and Len Prange put forth a positive picture for AccuMed during this formal meeting on January 29, 1998. In my discussions with AccuMed, including last week, I have heard nothing that seems to suggest that AccuMed's position has changed from what Len told me in December. We must now just sit back and wait!

AccuMed will probably hear from NASDAQ this week. I am expecting them to retain their National NASDAQ listing. However, should I be wrong, I would expect them to drop only to the NASDAQ Small Cap listings. I don't see how they could drop to the level of a Bulletin Board listing. Remember, they were only about $500,000 short of meeting the requirement for maintaining a National NASDAQ listing on September 30, 1997. I would have been more concerned if Peter Gombrich resignation was related to the NASDAQ question, but we have been formally told that it wasn't.

Also, we are expecting earnings to be released within the next 2 weeks. I believe that the price is currently heavily discounted because of the Peter Gombrich's resignation, the NASDAQ question, and the expected so-so earnings report. If things go as I am hoping to see over the next two weeks, we may seen significant increase in the price after these concerns are past.

Cisco



To: MIKE DOOLEY who wrote (1405)2/9/1998 7:07:00 PM
From: CARYTRE  Read Replies (1) | Respond to of 1894
 
Mike,

You are right about the current net equity shortfall. A reversal of sales and earnings is not going to help the situation.

Hopefully this issue will dissolve and disappear as sales take off.

Regarding valuation, please read some of my earlier "FLUFF ANALYSIS" postings. Accumed is way undervalued compared to its peer group.

A fair market value based on a relative comparison is about $8 per share.

Cheers, C.S.